Profit Investment Management’s Viking Therapeutics VKTX Stock Holding History

Profit Investment Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$633K	Sell	17,995 -58,559	-76%	-$2.07M	2.56%	18
2025 Q3	$2.01M	Sell	76,554 -40,298	-34%	-$1.2M	2.53%	11
2025 Q2	$3.1M	Sell	116,852 -917	-0.8%	-$24.1K	2.79%	7
2025 Q1	$2.84M	Buy	117,769 +44,055	+60%	+$1.39M	2.64%	8
2024 Q4	$2.97M	Buy	73,714 +5,713	+8%	+$326K	2.38%	7
2024 Q3	$4.31M	Sell	68,001 -32,222	-32%	-$1.89M	3.39%	1
2024 Q2	$5.31M	Buy	100,223 +4,142	+4%	+$272K	3.33%	2
2024 Q1	$7.88M	Sell	96,081 -90,841	-49%	-$4.04M	4.45%	1
2023 Q4	$3.48M	Buy	+186,922	New	+$2.44M	1.99%	20

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Profit Investment Management's VKTX Position: Q4 2025 in Review

Profit Investment Management reduced its Viking Therapeutics (VKTX) stake by 76% in Q4 2025, selling an estimated $2.07M and leaving 17,995 shares worth $633K. The position accounts for 2.56% of the portfolio, ranked #18.

Profit Investment Management first reported a position in VKTX in Q4 2023 and has held it in 9 quarters since. The position peaked at $7.88M in Q1 2024. 424 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

Profit Investment Management held 17,995 shares of Viking Therapeutics worth $633K as of Q4 2025.
Profit Investment Management sold 58,559 Viking Therapeutics shares in Q4 2025, an estimated $2.07M.
Viking Therapeutics made up 2.56% of Profit Investment Management's portfolio in Q4 2025, its #18 holding.
Profit Investment Management first reported a position in Viking Therapeutics in Q4 2023 and has held it in 9 quarters since.
Profit Investment Management's Viking Therapeutics position peaked at $7.88M in Q1 2024.
424 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Profit Investment Management's 13F filing for Q4 2025, filed 8 Jan 2026.